5-140698546-G-T

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1

The NM_012208.4(HARS2):​c.1515G>T​(p.Glu505Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000546 in 1,611,890 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.000066 ( 1 hom., cov: 33)
Exomes 𝑓: 0.000053 ( 1 hom. )

Consequence

HARS2
NM_012208.4 missense

Scores

2
17

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:1

Conservation

PhyloP100: 0.256

Publications

1 publications found
Variant links:
Genes affected
HARS2 (HGNC:4817): (histidyl-tRNA synthetase 2, mitochondrial) Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. The protein encoded by this gene is an enzyme belonging to the class II family of aminoacyl-tRNA synthetases. Functioning in the synthesis of histidyl-transfer RNA, the enzyme plays an accessory role in the regulation of protein biosynthesis. The gene is located in a head-to-head orientation with HARS on chromosome five, where the homologous genes likely share a bidirectional promoter. Mutations in this gene are associated with the pathogenesis of Perrault syndrome, which involves ovarian dysgenesis and sensorineural hearing loss. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]
ZMAT2 (HGNC:26433): (zinc finger matrin-type 2) Predicted to enable DNA binding activity and zinc ion binding activity. Involved in mRNA splicing, via spliceosome. Located in nucleus. Part of U2-type precatalytic spliceosome. [provided by Alliance of Genome Resources, Apr 2022]
ZMAT2 Gene-Disease associations (from GenCC):
  • congenital radioulnar synostosis
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.02610445).
BP6
Variant 5-140698546-G-T is Benign according to our data. Variant chr5-140698546-G-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 517495.
BS1
Variant frequency is greater than expected in population eas. GnomAdExome4 allele frequency = 0.0000534 (78/1459564) while in subpopulation EAS AF = 0.000605 (24/39686). AF 95% confidence interval is 0.000416. There are 1 homozygotes in GnomAdExome4. There are 42 alleles in the male GnomAdExome4 subpopulation. Median coverage is 29. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
HARS2NM_012208.4 linkc.1515G>T p.Glu505Asp missense_variant Exon 13 of 13 ENST00000230771.9 NP_036340.1 P49590-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
HARS2ENST00000230771.9 linkc.1515G>T p.Glu505Asp missense_variant Exon 13 of 13 1 NM_012208.4 ENSP00000230771.3 P49590-1

Frequencies

GnomAD3 genomes
AF:
0.0000591
AC:
9
AN:
152208
Hom.:
1
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000393
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000385
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.0000835
AC:
21
AN:
251482
AF XY:
0.0000809
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00109
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000534
AC:
78
AN:
1459564
Hom.:
1
Cov.:
29
AF XY:
0.0000578
AC XY:
42
AN XY:
726304
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33438
American (AMR)
AF:
0.00
AC:
0
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26132
East Asian (EAS)
AF:
0.000605
AC:
24
AN:
39686
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86206
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53418
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5766
European-Non Finnish (NFE)
AF:
0.00000360
AC:
4
AN:
1109868
Other (OTH)
AF:
0.000812
AC:
49
AN:
60328
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.467
Heterozygous variant carriers
0
4
8
12
16
20
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000656
AC:
10
AN:
152326
Hom.:
1
Cov.:
33
AF XY:
0.00
AC XY:
0
AN XY:
74502
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41578
American (AMR)
AF:
0.000392
AC:
6
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.000386
AC:
2
AN:
5188
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10622
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68018
Other (OTH)
AF:
0.000946
AC:
2
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.511
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000378
ExAC
AF:
0.0000906
AC:
11
Asia WGS
AF:
0.000866
AC:
3
AN:
3478

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2
Mar 26, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 505 of the HARS2 protein (p.Glu505Asp). This variant is present in population databases (rs370053420, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with HARS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 517495). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

May 02, 2025
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis suggests that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -

Inborn genetic diseases Uncertain:1
Nov 29, 2021
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1515G>T (p.E505D) alteration is located in exon 13 (coding exon 13) of the HARS2 gene. This alteration results from a G to T substitution at nucleotide position 1515, causing the glutamic acid (E) at amino acid position 505 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

not specified Benign:1
Jul 25, 2017
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

p.Glu505Asp in exon 13 of HARS2: This variant is not expected to have clinical s ignificance due to a lack of conservation across species, including mammals. Of note, elephant, shrew, manatee, tenrec and aardvark have an Asp at this position despite high nearby amino acid conservation. In addition, computational predict ion tools do not suggest a high likelihood of impact to the protein. It has been identified in 0.1% (23/18870) of East Asian chromosomes by the Genome Aggregati on Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs370053420). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.073
BayesDel_addAF
Benign
-0.52
T
BayesDel_noAF
Benign
-0.57
CADD
Benign
8.6
DANN
Uncertain
0.98
DEOGEN2
Benign
0.076
T;.;.;.;.;.;.;T;T;.;T
Eigen
Benign
-0.64
Eigen_PC
Benign
-0.57
FATHMM_MKL
Uncertain
0.82
D
LIST_S2
Benign
0.67
.;.;.;T;T;T;T;.;T;T;T
M_CAP
Benign
0.0092
T
MetaRNN
Benign
0.026
T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.5
L;.;.;.;.;.;.;L;L;.;.
PhyloP100
0.26
PrimateAI
Benign
0.36
T
PROVEAN
Benign
-1.2
N;.;.;.;.;.;.;.;.;N;N
REVEL
Benign
0.020
Sift
Benign
0.14
T;.;.;.;.;.;.;.;.;T;T
Sift4G
Benign
0.26
T;.;.;.;.;.;.;.;.;T;T
Polyphen
0.0010
B;.;.;.;.;.;.;B;B;.;B
Vest4
0.079
MutPred
0.29
Gain of MoRF binding (P = 0.1131);.;.;.;.;.;.;Gain of MoRF binding (P = 0.1131);Gain of MoRF binding (P = 0.1131);.;.;
MVP
0.37
MPC
0.14
ClinPred
0.041
T
GERP RS
-1.4
PromoterAI
-0.0060
Neutral
Varity_R
0.034
Mutation Taster
=86/14
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs370053420; hg19: chr5-140078131; API